Ketamine: Nursing Drug Guide, Airway Monitoring & NCLEX Review
Healthcare medication guide focused on ketamine airway and ventilation safety: rapid IV respiratory risk, 100 mg/mL dilution checks, emergence reactions, and CNS depressant co-administration hazards.
Ketamine can still cause serious respiratory depression when administered rapidly IV, in overdose, or with other CNS depressants. The 100 mg/mL concentration must be diluted before IV use per prescribing information, and concentration confusion is a high-alert failure point. Emergence reactions can escalate from restlessness to severe hallucinations and agitation. Airway reflexes are commonly preserved when ketamine is used alone, but this does not replace continuous airway, breathing, and sedation monitoring.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every ketamine dose, verify concentration, dilution, and monitoring capability. Use paced IV administration, continuous breathing assessment, and early escalation for declining ventilation or severe emergence phenomena.
Most common brand names
Ketamine is commonly supplied as ketamine hydrochloride injection under KETALAR and generic equivalents. Label strengths include 10 mg/mL, 50 mg/mL, and 100 mg/mL vials. For nursing safety, read vial concentration first, then confirm route and dilution requirements in the order.
The 100 mg/mL concentration must be diluted before IV administration per the reviewed prescribing information. This page focuses on injectable inpatient use where airway support and skilled monitoring are immediately available.
Why we give it — Indications
Ketamine is used for induction and maintenance of anesthesia and procedural sedation in monitored settings. It is frequently paired with other sedatives like midazolam or propofol, which raises airway and breathing risk when effects overlap.
| Use | Detail |
|---|---|
| Anesthesia induction | Prescribing information lists ketamine for induction of anesthesia by IV or IM routes in appropriately monitored settings. |
| Anesthesia maintenance support | Maintenance may be achieved with supplemental IV increments or additional IM doses, titrated to response with continuous airway and cardiorespiratory monitoring. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Ketamine produces dissociative anesthesia primarily via NMDA receptor antagonism. Airway reflexes are often better preserved when ketamine is used alone, but rapid IV administration, high dose exposure, and combined CNS depressants (including diazepam) can still lead to dangerous hypoventilation and airway events. Emergence reactions are a parallel nursing safety focus.
Dosing overview
Dosing must be individualized and titrated under close monitoring. Verify mg/kg calculation, concentration selection, and route before administration. The reviewed KETALAR label states that 100 mg/mL must be diluted before IV use.
Renal/hepatic dose adjustment: Not specified in the reviewed prescribing information.
Missed dose: Not applicable to most procedural or anesthesia induction regimens. For maintenance increments, follow anesthesia or prescriber protocol and reassess airway status before any supplemental dose.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (IV) | Rapid (seconds) | Rapid IV push increases respiratory risk; remain at bedside during and after administration |
| Clinical duration | Short anesthetic window, recovery varies | Continue monitoring through emergence because delayed hypoventilation and agitation can appear |
| Distribution/elimination | Rapid distribution with hepatic metabolism | Trend response alongside baseline liver function tests when clinically indicated |
| Supportive labs | Case-dependent monitoring | Pair dose planning with baseline status such as electrolyte panel results when relevant |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Confirm airway equipment, oxygen, suction, and skilled support are available before administration
- Review concurrent sedatives and complete medication reconciliation before combining ketamine with other CNS depressants
- Verify weight-based dose, vial strength (10/50/100 mg/mL), and required dilution for IV route
Contraindications
- Known hypersensitivity to ketamine or formulation components
- Any clinical context where significant blood pressure elevation would be a serious hazard per reviewed prescribing information
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Benzodiazepines, opioid analgesics (e.g. morphine), or other CNS depressants | Profound sedation, respiratory depression, coma, or death per labeling; opioids may prolong recovery | Clarify sequencing and dosing with prescriber/pharmacy; monitor neurologic status, respiratory rate, and pulse oximetry continuously when co-administered |
| Aminophylline or theophylline | Concomitant use may lower the seizure threshold | Consider an alternative to ketamine when theophylline or aminophylline is required; escalate to prescriber/pharmacist |
| Sympathomimetics and vasopressin | May enhance ketamine sympathomimetic effects (BP and HR elevation) | Closely monitor vital signs; consider individualized dose adjustment per labeling |
| Rapid IV administration | Respiratory depression and enhanced vasopressor response per labeling | Administer IV induction over 60 seconds; remain at bedside with airway support ready |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous or intramuscular ketamine injection. Ketamine is a Schedule III controlled substance—follow controlled-medication handling and IV medication administration policy.
- Administer IV induction over 60 seconds; avoid rapid IV push
- Dilute the 100 mg/mL product before IV use and document final concentration
- Use an independent double-check for mg/kg calculation, drawn volume, and route
- Document dose, route, dilution, airway status, BP trend, and recovery behavior after administration
Ketamine vials come in 10, 50, and 100 mg/mL strengths. The 100 mg/mL concentration must be diluted before IV use. Concentration selection and dilution errors are preventable high-alert failures.
Expected therapeutic response
- Adequate procedural dissociation or analgesic response on standardized pain assessment when relevant
- Stable respiratory pattern and oxygenation on ongoing pulse oximetry monitoring
- No severe emergence symptoms and no hemodynamic deterioration requiring urgent intervention
Red flags — Stop and act
Ketamine deterioration can appear as abrupt hypoventilation, airway compromise, or severe emergence reaction. Escalate quickly; do not assume airway reflexes alone guarantee safe ventilation.
- Absent or weak respiratory effort consistent with apnea
- Worsening oxygenation or visible difficulty breathing despite oxygen
- Marked excessive sleepiness or persistent confusion
- Distressing hallucinations with escalating agitation
- Blood pressure rise reaching unsafe limits for that patient context
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Respiratory depression / apnea | Serious, especially with rapid IV use or sedative stacking | Stop administration, support airway and ventilation, and escalate immediately |
| Emergence reactions | Occurred in approximately 12% of patients in reviewed labeling | Minimize verbal, tactile, and visual stimulation; consider benzodiazepine per prescriber for severe symptoms |
| Hypertension and tachycardia | Common sympathomimetic effect | Trend hemodynamics and intervene when rise is unsafe for patient profile |
| Nausea and vomiting | Common | Protect airway, provide supportive care, and reassess aspiration risk |
| Hypersensitivity / anaphylaxis | Reported; may be serious | Discontinue ketamine and manage per local anaphylaxis protocol |
| Nystagmus/diplopia/sedation variability | Dose-related | Use combined respiratory and neurologic reassessment before further dosing |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Ketamine overdose may present with profound sedation, respiratory depression, and cardiorespiratory instability. Although ketamine often preserves airway reflexes when used alone, overdose and rapid IV administration can still produce life-threatening ventilatory failure.
Early signs
- Declining respiratory effort, poor air entry, or obstructed breathing pattern
- Severe behavioral dyscontrol with worsening oxygenation and hemodynamic instability
Antidote
No specific antidote is listed for ketamine overdose in the reviewed prescribing information. Management is supportive: airway positioning, oxygenation, assisted ventilation including bag-valve-mask ventilation or mechanical ventilation as needed, hemodynamic monitoring, and urgent senior escalation. Labeling notes patients had prolonged but complete recovery after unintentional overdose up to ten times the usual dose.
Contact local poison control or medical toxicology services for overdose guidance per facility protocol and local emergency guidance. Maintain airway and ventilation while awaiting specialist input.
Look-alike / sound-alike and error prevention
- 10 mg/mL vs 50 mg/mL vs 100 mg/mL—verify vial strength before draw-up
- Dilution failure—100 mg/mL concentration must be diluted before IV administration
- mg/kg arithmetic errors—independent double-check required for induction doses
- Route mismatch—do not assume IV/IM interchangeability without explicit order
- Anesthesia tray look-alikes—scan and confirm every vial at bedside
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Before administration | Read concentration aloud during independent double-check and confirm IV dilution plan. |
| IV technique | Deliver induction dose over 60 seconds and observe chest movement continuously. |
| Recovery environment | Minimize stimulation to reduce severity of emergence reactions. |
| Behavioral safety | Protect airway and lines if severe agitation develops; call for immediate assistance. |
| Documentation | Record mg/kg dose, concentration, dilution, route, and post-dose airway/hemodynamic findings. |
| Ask pharmacy when | Concentration conversion is unclear or sedative co-administration increases safety concern. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Concurrent CNS depressant exposure | Additive sedation and respiratory compromise risk rises when ketamine is combined with sedatives or opioids. |
| Reduced respiratory reserve | Baseline breathing vulnerability increases danger from rapid IV administration or oversedation. |
| Patients vulnerable to BP surges | Ketamine-related blood pressure increase may be a serious hazard and requires individualized hold thresholds. |
| Pediatrics and low-weight adults | Weight-based dosing errors are more likely; independent mg/kg verification is essential. |
| History of severe emergence reactions | Needs anticipatory recovery planning with calm environment and rapid behavioral escalation strategy. |
| Pregnancy | Available human data mostly describe ketamine at cesarean section without identified drug-associated maternal or fetal outcome risk; data are limited. Animal and nonclinical data suggest potential developmental neurotoxicity with prolonged exposure. Balance procedural necessity with prescriber-led risk discussion. |
| Lactation | Ketamine and metabolite are present in human milk per labeling; infant sedation, respiratory depression, and increased muscle tone/spasms are potential concerns. KETALAR treatment in lactating women should be limited to anesthesia; monitor breastfed infants when used. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Respiratory pattern, airway patency, sedation depth, blood pressure, and pulse trend per protocol
- Continuous pulse oximetry and capnography when available, especially after IV induction
- Serial level of consciousness checks and early emergence-behavior surveillance
Document
- Dose (mg/kg and total mg), concentration, dilution details, route, time, and independent double-check completion
- Pre/post airway and hemodynamic assessments and any emergence reactions with interventions used
- Escalation actions, response timeline, and handoff details for ongoing surveillance
Patient teaching
- Ketamine can still impair breathing, especially with rapid IV use or sedative combinations; report breathing changes immediately
- Recovery reactions may include vivid dreams or disorientation; staff will monitor and support safe reorientation
- Do not combine unapproved sedatives or alcohol with ketamine treatment plans
- For suspected overdose, follow local emergency guidance and contact local poison control or toxicology services per protocol
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to ketamine or formulation components
- Patient condition where significant BP elevation would be a serious hazard
- Worsening ventilation or airway concern before next planned dose
- Unclear concentration, missing IV dilution plan for 100 mg/mL, or mg/kg mismatch on independent check
- Concomitant CNS depressants without a clear monitoring and escalation plan
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Ketamine is a Schedule III controlled medication with two linked nursing hazards: airway compromise from rapid IV/overdose or sedative stacking, and emergence reactions that destabilize recovery. Treat concentration selection as a high-alert medication workflow with paced IV technique and post-dose behavioral plus respiratory reassessment.
1. Check-before-you-give protocol
- Right patient, right drug, right mg/kg dose, right concentration, right route, right dilution, and right IV pace
- Independent double-check for 10/50/100 mg/mL vial selection and drawn volume
- Confirm airway equipment, oxygen, suction, and escalation pathway before giving dose
- Baseline breathing, blood pressure, and consciousness documented before dosing
2. High-alert and safety badge
Schedule III controlled anesthetic — concentration-critical IV useReviewed KETALAR labeling includes IV induction over 60 seconds, IM induction ranges, and dilution requirements for 100 mg/mL IV use.
3. Clinical workflow: hold and question rules
- If breathing quality worsens or airway obstruction appears, hold repeat ketamine and escalate immediately
- If severe emergence reaction occurs, prioritize safety, low-stimulus care, and rapid senior review
- In suspected overdose, provide supportive ventilation and contact local poison control or toxicology services
4. Critical teach-back questions
- “What breathing or alertness changes should you report immediately after ketamine?” (Patient should identify breathing difficulty, extreme sleepiness, or inability to stay oriented.)
- “Why do nurses keep the room calm and keep checking you in recovery?” (Patient should understand emergence reactions and delayed respiratory events can occur.)
5. Care coordination
Pharmacist: Consult for concentration verification, dilution support, and safe co-sedation planning
Prescriber / anesthesia: Notify for respiratory compromise, severe emergence reaction, or unsafe hemodynamic response
🧠 Quick mental checklist
- What concentration is this vial, and is IV dilution required before giving?
- Am I delivering IV ketamine over the recommended time rather than as a rapid push?
- What concurrent sedatives were given that could worsen respiratory compromise?
- Are airway equipment and escalation support immediately available at bedside?
- Have I reassessed breathing, blood pressure, and emergence behavior before repeat dosing?
Ketamine NCLEX practice questions
Practice NCLEX-style clinical judgment practice for ketamine using a tabbed case panel (MAR, labs, vitals, nursing notes), then rotate priority action, SATA cue recognition, trend interpretation, matrix urgency sorting, and cloze safety decisions—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Ketamine 2 mg/kg IV induction ordered over 60 seconds at 1415 (weight 70 kg = 140 mg)
- Vial available: ketamine 100 mg/mL, 5 mL
- Midazolam 1 mg IV documented at 1410
- 1.4 mL ketamine drawn from 100 mg/mL vial; dilution step not documented in MAR
- Baseline electrolytes and renal profile within local reference range
- Mildly elevated liver enzymes, unchanged from pre-op baseline
- No antidote medication available; ketamine overdose management is supportive ventilation and escalation
- 1415 pre-dose: RR 16, SpO2 97% room air, BP 132/78
- 1420: RR 10 shallow, SpO2 92% room air, BP 166/94
- 1424: RR 8 with intermittent obstruction sounds, SpO2 89% on 4 L/min, BP 174/98
- Patient reports frightening visual experiences and repeatedly removes oxygen cannula
- Airway reflexes still present to suction stimulation, but ventilation trend is worsening
- Charge nurse asks whether 100 mg/mL vial was diluted before IV administration
- Anesthesia provider en route; bag-mask setup at bedside
Answer key & rationale
Frequently asked questions
What is the main nursing safety danger with ketamine?
The key danger is respiratory compromise when ketamine is pushed rapidly IV, overdosed, or combined with other CNS depressants. Airway reflexes are often preserved when ketamine is used alone, but this does not replace active airway and ventilation monitoring.
What induction doses are listed in the reviewed KETALAR labeling?
IV induction is 1 to 4.5 mg/kg over 60 seconds (average 2 mg/kg), and IM induction is 6.5 to 13 mg/kg. Maintenance uses supplemental IV increments or additional IM dosing based on response.
Why is the 100 mg/mL ketamine vial high risk for IV administration?
The 100 mg/mL concentration must be diluted before IV use per prescribing information. Undiluted IV use increases medication-error potential and adverse-event risk.
Is there a specific antidote for ketamine overdose?
No specific antidote is listed in the reviewed prescribing information. Management is supportive with airway protection, oxygenation and ventilation support, hemodynamic monitoring, and urgent escalation.
When should ketamine be held and clarified before administration?
Hold for hypersensitivity, cases where significant blood pressure elevation is a serious hazard, unclear concentration or dilution instructions, and unsafe CNS depressant co-administration plans.
References
-
U.S. National Library of Medicine. KETALAR (ketamine hydrochloride injection) prescribing information. DailyMed (March 2026 label).https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e8f864-8b8a-4e7e-8439-e510d3107063
-
U.S. Drug Enforcement Administration. Drug Scheduling.https://www.dea.gov/drug-information/drug-scheduling
-
Institute for Safe Medication Practices. High-Alert Medications in Acute Care Settings.https://www.ismp.org/recommendations/high-alert-medications-acute-list
-
American Society of Anesthesiologists. Practice guidelines for moderate procedural sedation and analgesia.https://pubs.asahq.org/anesthesiology/article/128/3/437/18824/Practice-Guidelines-for-Moderate-Procedural
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.